Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.67 |
| ▸ | KDR | P35968 | 8/20 | 0.65 |
| ▸ | RET | P07949 | 3/20 | 0.65 |
| ▸ | BRAF | P15056 | 3/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | KIT | P10721 | 2/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.65 |
| ▸ | FLT1 | P17948 | 2/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.65 |
| ▸ | TTK | P33981 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733289 | 1.00 | RAF1 (0.67) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL14481108 | 0.94 | RAF1 (0.60) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL15114776 | 0.91 | KDR (0.68) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL29746661 | 0.91 | KDR (0.68) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL548163 | 0.90 | RAF1 (0.64) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL549150 | 0.89 | RAF1 (0.56) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL549118 | 0.89 | RAF1 (0.65) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL14680565 | 0.88 | RAF1 (0.56) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL31323421 | 0.88 | RAF1 (0.54) | RAF1KDRRETBRAFAURKB | |
| SCHEMBL29523346 | 0.86 | KDR (0.59) | RAF1KDRRETBRAFAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181188-B2 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2015-11-10 | — | — | US | claimed |
| US-20120136157-A1 | ARYL UREAS AS KINASE INHIBITORS | DUMAS JACQUES (US) | 2012-05-31 | — | — | US | claimed |
| EP-1580188-B9 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-23 | — | — | EP | claimed |
| US-8110587-B2 | Antiinflammatory agents; anticancer agents; osteoporosis | BAYER HEALTHCARE LLC (US) | 2012-02-07 | — | — | US | claimed |
| EP-1580188-B1 | Aryl ureas as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2011-10-19 | — | — | EP | claimed |
| JP-4527401-B2 | — | — | 2010-08-18 | — | — | JP | claimed |
| EP-1580188-A1 | Aryl ureas as kinase inhibitors | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | claimed |
| JP-2005523278-A | — | — | 2005-08-04 | — | — | JP | claimed |
| EP-1474393-A1 | ARYL UREAS AS KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-11-10 | — | — | EP | claimed |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | BAYER CORPORATION (US) | 2003-11-20 | — | — | US | claimed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | PHARMACOSMOS HOLDING A/S (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20070265315-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC | 2007-11-15 | — | — | US | disclosed |
| EP-1580188-A1 | Aryl ureas as kinase inhibitors | Bayer Pharmaceuticals Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1474393-A1 | ARYL UREAS AS KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | BAYER CORPORATION (US) | 2003-11-20 | — | — | US | disclosed |
| WO-2003068746-A1 | ARYL UREAS AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265315-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | MAP2K2, MAP3K7, MAP4K2 | RAF1 45/4885KDR 43/4885RET 145/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | RAF1 2086/4885KDR 1718/4885RET 2471/4885 |
| US-12565502-B2 | Substituted 1′,2′-dihydro-3′h-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c] [1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors | CCNO, CDK2, CCNI | RAF1 268/4885KDR 361/4885RET 403/4885 |
| US-20030216446-A1 | Aryl ureas as kinase inhibitors | MAPK1, MAP3K1, MAP3K6 | RAF1 47/4885KDR 40/4885RET 107/4885 |
| US-20120136157-A1 | ARYL UREAS AS KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K6 | RAF1 47/4885KDR 40/4885RET 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.